Treatment of focal anaplastic Wilms tumor: A report from the Children’s Oncology Group AREN0321 and AREN03B2 studies

Armstrong AE, Daw NC, Renfro LA, Geller JI, Kalapurakal JA, Khanna G, Paulino AC, Perlman EJ, Ehrlich PF, Gow KW, Warwick AB, Grundy PE, Fernandez CV, Mullen EA, Dome JS; Children’s Oncology Group AREN0321 and AREN03B2 Study Committees. Treatment of focal anaplastic Wilms tumor: A report from the Children’s Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025 Jan 15;131(2):e35713. doi: 10.1002/cncr.35713. PMID: 39803937; PMCID: PMC12128929.

On the fifth National Wilms Tumor Study, patients received vincristine and dactinomycin (VA) without radiation for stage I focal anaplastic Wilms tumor (FAWT) and VA plus doxorubicin (DD4A) and radiation for stage II-IV FAWT. The 4-year event-free survival (EFS) and overall survival (OS) for stage I and stage IV FAWT were 67.5% and 88.9% and 61.4% and 71.6%, respectively. Therapy intensification for stage I and IV FAWT were evaluated as secondary objetives on AREN0321.